Nordic Adjuvant IFN Melanoma Trial

NCT01259934 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

855

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Adjuvant Therapy

Interventions

DRUG: Interferon-alpha2b - 1 year
DRUG: Interferon-alpha2b - 2 years

Sponsor

Karolinska Institutet

Collaborators

[object Object]